antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
Search
Martin Stefanic
Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Innovating for our business
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Is artificial intelligence the future of farming?
Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
The first liquid solution for hypertension in cats
Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Launch of BVDzero scholarship for veterinary students
Launch of BVDzero scholarship for veterinary students globally
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Award winning employers
Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
commitments to sustainable development
On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
Netherton syndrome (NS)
Information on Netherton syndrome (NS), a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Arti-cell Forte stem cell-based veterinary product
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
The Boehringer Ingelheim Veterinary Scholars Program
The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Avian influenza prevention at the source
Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
Transforming Science Day Europe
Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.